Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cellular Pump Sabotages Cancer Drug Studies that use Glow Chemical

Published: Thursday, January 03, 2008
Last Updated: Thursday, January 03, 2008
Bookmark and Share
Scientists discover that a widely used means of illuminating cancer cells could undermine studies of the potential value of experimental anti-cancer drugs.

Johns Hopkins scientists have by chance discovered that a widely used means of illuminating cancer cells could undermine studies of the potential value of experimental anti-cancer drugs because the natural “pump” that cells use to clear out the chemical light source alters their chemistry.

“Researchers who use markers involving luciferase may want to double-check their findings,” says Martin Pomper, M.D., Ph.D., associate professor of radiology, oncology, and pharmacology and molecular sciences at Johns Hopkins.

Scientists have increased their use of glowing markers to track cellular activity in rats and mice, in part, because the tactic is non-invasive and more humane for the animals.

To make the cells glow, scientists use a gene encoding luciferase, an enzyme that causes a chemical reaction responsible for the tiny glow in fireflies. Researchers transfer the luciferase gene into the genetic machinery of cancer cells, which then are injected into an animal, and the enzyme’s glow signals the response of a cell to an anticancer drug.

But in a chance discovery, Pomper, collaborating with John Laterra, M.D., Ph.D., professor of neurology, neuroscience and oncology at Johns Hopkins and the Kennedy Krieger Institute, found that a cellular “pump” that automatically rids cancer cells of its glowing contents over time, can distort test results. They stumbled on the saboteur pump during experiments with a bioluminescent marker in mice that is designed to test the effect of an experimental drug on a cancer-causing gene pathway, called hedgehog.

Pomper’s work focused on an anti-hedgehog compound called HhAntag-691 that his team hoped would turn off the pathway with a single dose. The way the study was designed, his team first bioilluminated the cancer cells with the luciferase gene, then introduced HhAntag-691 into the animals. If it worked, researchers would see no glow in the cancer cells because the hedgehog pathway would be switched off, failing to activate other components in the hedgehog pathway that turn on luciferase.

“But when we added the anti-hedgehog compound, the cells glowed brighter rather than getting dimmer,” says Pomper, whose team from the Johns Hopkins Kimmel Cancer Center and Russell H. Morgan Department of Radiology observed a threefold increase in glow output. The glow is measured by means of a photograph taken through the animal’s skin with a camera that detects bioluminescent wavelengths. “We thought this was bizarre and repeated the experiment many times.”

In an effort to figure out their problem, the researchers repeated the experiment in a cell extract, a replica of the cell environment without the intact cell itself. In this test, the glow dipped threefold. “This suggested that natural pumps on the surfaces of intact cancer cells pump out luciferin, which reacts with intracellular luciferase to cause the cells to glow,” said Pomper, whose report on the subject appeared in the October 1 issue of Cancer Research.

Pomper’s team identified the chemical pump, called ABCG2/BCRP, which is one of nearly 50 of its type. And they warn drug developers to be wary of it.

“If you want to use bioluminescence to test a drug’s action, make sure the cells don’t have this pump,” says Pomper.

The trouble is that many cancers express this pump, and shutting it off would complicate the test, according to Pomper. Still, the discovery has tipped off the researchers to a new target and a test to find inhibitors of it.

“We’re now looking for inhibitors of the pump, which when coupled with standard chemotherapy, could lead to less drug resistance than currently seen for most tumors,” says Pomper.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tumor-Only Genetic Sequencing May Misguide Cancer Treatment in Nearly Half of All Patients
Johns Hopkins scientists say the genetic code of tumors must be compared to patients’ noncancer genome to get a true picture.
Thursday, April 16, 2015
New Genetic and Epigenetic Contributors to Diabetes Identified
Comparison of fat cells in mice and men hints at how genes and environment conspire to produce disease.
Wednesday, January 07, 2015
When DNA Gets Sent to Time-Out
New details revealed in the coordinated regulation of large stretches of DNA.
Tuesday, January 06, 2015
CRISPR Shows Promise in Engineering Human Stem Cells
Johns Hopkins study could advance use of stem cells for treatment and disease research.
Monday, January 05, 2015
Up-close Look at Cancer on the Move
Microscopic view of metastasis could give insight about how to keep cancer in check.
Friday, November 07, 2014
Potential New 'Twist' in Breast Cancer Detection
Mouse studies reveal new and better picture of stem cells that may fuel some breast cancers.
Monday, December 07, 2009
Johns Hopkins Researchers Develop Human Stem Cell Line Containing Sickle Cell Anemia Mutation
Researchers establish a human cell-based system for studying the disease by reprogramming somatic cells to an embryonic stem cell like state.
Tuesday, June 03, 2008
Johns Hopkins Researcher Leads International Effort to Create “Proteinpedia”
A Johns Hopkins researcher has led the effort to compile to date the largest free resource of experimental information about human proteins.
Thursday, February 07, 2008
RNA Shown to Silence Cancer Suppressor Gene
Discovery sheds light on epigenetic mechanisms in tumor development in plants and animals.
Tuesday, January 15, 2008
More Functional DNA in Genome than Previously Thought
Hopkins researchers report that non-coding DNA, that contributes to inherited diseases like Parkinson’s or mental disorders, may be more abundant than we realize.
Thursday, December 20, 2007
Omicia and Johns Hopkins Receive Small Business Technology Transfer Grant from NIH
Omicia recieves a $187,700 grant from NIH to support a collaboration with Johns Hopkins University to identify genetic causes of cardiovascular disease.
Friday, August 17, 2007
Key to Lung Cancer Chemo Resistance Revealed
Products made by a gene called NRF2 normally protect cells from environmental pollutants.
Tuesday, October 17, 2006
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!